Proactive Investors - Run By Investors For Investors

THC Global Group expands into Asia with partnership

THC has partnered with a Malaysian bio-tech firm to deliver medicinal cannabis products.
cog with word collaboration on it
This partnership allows THC to be a first-mover in targeted Asian countries

THC Global Group Ltd (ASX:THC) has secured a mutually exclusive partnership with Malaysian agri-tech company Heleogenics Sdn Bhd.

This represents a significant first step in the company’s Asian markets strategy.

The partnership with Heleogenics is initially to liaise with the Malaysian government towards the legalisation of medicinal cannabis in Malaysia.

The two will then explore other nations within Asia and the Middle East where there may be opportunities for THC Global to enter the medicinal cannabis market.

READ: THC Global acquires site in Canada for cannabis production

THC Global’s CEO Ken Charteris said: “Working with the Heleogenics team, who are leaders in the bio-tech and agri-tech sector within Asia brings a significant wealth of experience both within government liaison in addition to broadening the company’s research and development capabilities.

“In securing commercial partnerships with established businesses like Heleogenics within Asia, we are able to enter markets in an accelerated manner as soon as legislative changes are made, ensuring a first-to-market approach with significantly lower capital outlay than operating solely.”

Heleogenics is a valuable partner

Heleogenics is associated with Sengenics, a global medical bio-tech company primarily focussed on proteomics for medical diagnostics and the development of novel therapies.

Sengenics’s shareholders include SBI Holdings (SoftBank) and Insas Berhad.

The partnership will also encompass exploration of the significant agri-tech experience in plant genomics of Heleogenics, as well as THC’s expertise and IP in medicinal cannabis.

THC’s scope of activity in Asia includes developing patient access, doctor and patient engagement, off-take agreements and sales, R&D, and IP commercialisation.

View full THC profile View Profile

THC Global Group Ltd Timeline

Related Articles

man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
Surgery
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use